Probiotics can provide a comprehensive solution for oral healthcare, offering benefits such as improved oral health and a reduced risk of dental diseases.

- Probiotics offer a complete oral healthcare package. - They can help prevent dental caries and periodontal diseases. - Probiotics can also reduce bad breath and improve overall oral health. - Regular use of probiotics can be beneficial for maintaining oral hygiene. - Probiotics are a safe and natural alternative to traditional oral care products.

This is from Journal in 2024 at URL.

Probiotics may have potential therapeutic benefits in the prevention and treatment of COVID-19, as they can modulate the immune response and alleviate symptoms, according to a systematic review of current evidence.

- Probiotics can help control inflammation and reduce mortality and morbidity by strengthening the immune system. - Some probiotics may alleviate symptoms and severity of COVID-19, such as diarrhea, cough, anosmia, and weakness. - Probiotics may have antiviral effects and can modulate the immune response against COVID-19. - Bifidobacterium and Lactobacillus strains have shown positive effects in managing COVID-19. - Probiotics can improve gut microbiota and reduce the risk of secondary infections. - Probiotics may play a role in preventing and treating COVID-19, but more research is needed.

This is from Journal in Year at URL.

Probiotic treatment with Lacticaseibacillus rhamnosus GG (LGG) as post-exposure prophylaxis for COVID-19 may reduce the likelihood of developing illness symptoms and delay the time to COVID-19 infection when used within 7 days of exposure, according to a double-blind, placebo-controlled randomized trial.

- Probiotic Lacticaseibacillus rhamnosus GG (LGG) may reduce the risk of developing COVID-19 symptoms. - LGG is associated with a prolonged time to COVID-19 infection and reduced incidence of illness symptoms when used as prophylaxis within 7 days of exposure. - Overall incidence of COVID-19 diagnosis did not significantly differ between LGG and placebo groups. - LGG may inform future COVID-19 prevention studies, especially in developing nations where Lacticaseibacillus probiotics have been used to reduce other infectious diseases.

This is from ClinicalTrials.gov in 2020 at this link.

The study investigated the effect of probiotics on the innate inflammatory response and viral shedding in experimental rhinovirus infection, finding that the administration of Bifidobacterium animalis subspecies lactis Bl-04 resulted in a reduction in the inflammatory response and viral shedding in the upper respiratory tract of human volunteers.

- Ingestion of the probiotic may be associated with an increased CXCL8 response in the nose at baseline that modifies the response to infection. - The probiotic Bl-04 may have reduced virus shedding in nasal secretions. - Probiotics have been shown to induce expression of antiviral responses in vitro and in animal models. - Probiotic supplementation may have a potential for preventing viral respiratory infection and illness. - Further investigations are needed to determine the effects of specific probiotics on innate immune function in the human host.

This is from Benef Microbes in 2017 at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797652/

The study investigated the systemic immune response to the oral probiotic Streptococcus salivarius BLIS K12 and found that its consumption led to changes in immune cell frequencies and cytokine production, suggesting potential health benefits.

- Consumption of the oral probiotic S. salivarius K12 may result in an anti-inflammatory systemic immune response. - Further studies with a larger cohort are needed to confirm these findings. - Understanding the mechanisms of probiotics' role in health is important.

This is from "Journal of [Gemma L. Laws, John D. F. Hale, and Roslyn A. Kemp] in 2021 at URL".

Probiotic therapy, in combination with chlorhexidine disinfection, can help reduce the severity of halitosis (bad breath) in children over longer periods of time.

- Probiotic therapy following oral disinfection with chlorhexidine may reduce the severity of halitosis over longer periods. - Mechanical and chemical oral hygiene practices alone may not significantly improve halitosis.

This is from Journal in 2023 at URL

The daily use of Streptococcus salivarius K12 (BLIS K12) has been associated with a significant reduction in streptococcal pharyngotonsillitis and other respiratory infections in children, suggesting its potential as a preventive measure against these diseases.

- Streptococcus salivarius K12 can be used to prevent streptococcal pharyngotonsillitis in children. - The use of Streptococcus salivarius K12 reduced streptococcal infections by approximately 90%. - Streptococcus salivarius K12 also showed potential in reducing tracheitis, viral pharyngitis, rhinitis, flu, laryngitis, acute otitis media, and enteritis. - Prophylactic administration of Streptococcus salivarius K12 could be a safe and cost-effective preventative measure for various pediatric infections. - The use of Streptococcus salivarius K12 may have anti-inflammatory, immunomodulating, and anti-viral effects. - Further studies are ongoing to understand the mechanisms and potential benefits of Streptococcus salivarius K12.

This is from Journal of Dentistry for Children in 2016 at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123729/

The use of a specific strain of Streptococcus salivarius, known as K12, may potentially improve oral and lung microbiotas and enhance defenses against SARS-CoV-2, the virus responsible for COVID-19.

- Streptococcus salivarius K12, a strain of bacteria, has been clinically demonstrated to create a stable upper respiratory tract microbiota that can protect against pathogenic bacteria, fungi, and viruses. - Streptococcus salivarius K12 has been shown to reduce the occurrence of viral upper respiratory tract infections, such as pharyngitis, tonsillitis, and otitis media. - The strain K12 can stimulate the release of interferon-gamma (IFN-γ) and activate natural killer cells without triggering aggressive inflammatory responses. - The presence of potentially pathogenic bacteria in the lungs of COVID-19 patients could increase the risk of secondary infection. - Streptococcus salivarius K12 may be considered as an adjunct to help control viral lung infections, associated pneumonias, and improve host immune functions.

This is from Minerva Med 2020 at https://www.minervamedica.it/en/journals/minerva-medica/article.php?cod=R10Y2020N03A0281.

The key takeaway of this article is that nutrition and probiotic therapy play an important role in the management of COVID-19, as they can support the immune system and improve the nutritional status of patients, potentially leading to better outcomes.

- Probiotics have potential uses in clinical practice. - Probiotics may be effective in managing childhood diarrhea. - Probiotics can alter gut microbiota and attenuate fecal inflammatory markers. - Probiotics have been studied for their potential role in respiratory virus infections. - Probiotics have been investigated for their effects on the immune response to influenza vaccination. - Probiotics may have beneficial effects in viral infections by affecting the innate and acquired immune systems. - Probiotics have been shown to protect human and animal intestinal epithelial and immune cells from enteric virus infection. - Probiotics may play a role in the treatment of COVID-19 patients and prevention of complications associated with increased antibiotic use. - Gut dysbiosis can impact secondary disease outcomes during viral respiratory infections. - Probiotics have been studied for their potential link to COVID-19.

This is from Nutrients in 2021 at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538178/

Oral bacteriotherapy, as a complementary treatment, showed potential benefits in reducing mortality rates in severe COVID-19 pneumonia patients, according to a retrospective cohort study.

- Oral bacteriotherapy may be beneficial for patients with COVID-19. - The gut-lung microbiota axis and high-fiber diet with probiotics may have anti-inflammatory effects in COVID-19 infection. - The commensal microbiota plays a role in viral infections. - Hypoalbuminemia, coagulopathy, and vascular disease are associated with COVID-19.

This is from Front. Nutr., 11 January 2021, at https://doi.org/10.3389/fnut.2020.613928.

The study suggests that oral bacteriotherapy, as a complementary therapeutic strategy, may help prevent the progression of COVID-19 by improving symptoms and reducing the risk of respiratory failure in patients with SARS-CoV-2 infection.

- Oral bacteriotherapy may be a complementary therapeutic strategy to prevent the progression of COVID-19. - The gut-lung axis and the gut microbiota play a role in lung immunity and respiratory diseases. - Short-chain fatty acids produced by the gut microbiota can ameliorate allergic lung inflammation. - Heme oxygenase-1, an enzyme with cytoprotective properties, has been shown to suppress the replication of respiratory viruses. - Probiotics and nutraceuticals have been studied as potential interventions for SARS-CoV-2 infection. - The use of probiotics is a topic of regulatory confusion and conflicting studies, with safety concerns.

This is from Frontiers in Medicine in 2020 at https://www.frontiersin.org/articles/10.3389/fmed.2020.00389/full.

The study investigated the effects of Streptococcus salivarius K12 probiotic on the saliva and nasopharyngeal microbiome in children attending daycare, and found that the use of S. salivarius K12 probiotic appeared to be safe and did not disrupt the normal microbiome in young children, although its impact on otopathogens in the nasopharyngeal microbiome remained uncertain.

- Streptococcus salivarius K12 has been evaluated in clinical trials for its potential benefits in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. - The safety of Streptococcus salivarius K12 has been assessed in various studies. - The impact of the 10-valent pneumococcal conjugate vaccine (PCV10) on the nasopharyngeal microbiome has been investigated. - The introduction of protein-polysaccharide conjugate vaccines has led to a decline in invasive pneumococcal disease. - The use of PCV10 has been associated with a reduction in antimicrobial use and tympanostomy tube placements. - The intestinal microbiome of pre-school children has been found to be related to lifetime antibiotic use. - The oral and nasopharyngeal microbiota have been shown to have a loss of microbial topography in relation to the development of respiratory infections in early life. - The clinical presentation of otitis media has been studied in relation to the impact of PCV on its pathogenesis. - Next-generation sequencing technologies have been used for microbiome analysis, but caution is needed to account for potential biases in PCR amplification and sequencing.

This is from Pediatric Infectious Disease Journal in 2021 at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043514/#

The preliminary study investigated the potential role of the oral probiotic Streptococcus salivarius K12 in improving the clinical outcomes of hospitalized COVID-19 patients, showing promising results in reducing the severity of the disease and potentially lowering the death rate.

- Streptococcus salivarius K12 has shown potential clinical effects in hospitalized COVID-19 patients. - It has been found to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children. - Streptococcus salivarius K12 may help prevent streptococcal pharyngo-tonsillitis, scarlet fever, and acute otitis media in 3-year-old children. - The oral use of Streptococcus salivarius K12 has shown promising results in reducing the occurrence of streptococcal and viral pharyngotonsillitis in children and adults. - Streptococcus salivarius K12 has been found to inhibit Candida albicans aggregation, biofilm formation, and dimorphism. - It has also demonstrated the ability to inhibit immune activation by periodontal disease pathogens. - Streptococcus salivarius K12 is being studied for its potential to reduce periodontal pathogen-induced inflammation. - Human systemic immune response to the ingestion of Streptococcus salivarius BLIS K12 has been observed.

This is from Microorganisms in 2022. You can find the article here.

The administration of S. salivarius K12 to children shows potential in reducing the rate of SARS-CoV-2 infection, according to preliminary research findings.

- The administration of S. salivarius K12 to children may reduce the rate of SARS-CoV-2 infection. - The oral microbiota may have a connection with the lung microbiota and could potentially alter susceptibility to viral infection. - The presence of certain bacterial species in the oral microbiota, such as Prevotella and Veillonella, may be associated with COVID-19 pneumonia. - The use of S. salivarius K12 as an oral probiotic has been proposed to reduce the risk of SARS-CoV-2 infection and/or COVID-19. - Preliminary results from a study with school-attending children showed that the administration of S. salivarius K12 was associated with a lower rate of SARS-CoV-2 infection. - Further research is needed to confirm these findings and translate them into clinical practice.

This is from Minerva Medica in 2021. You can find the article at this link.

The safety assessment of the oral cavity probiotic Streptococcus salivarius K12 showed that it is a safe and promising probiotic for oral health, with no adverse effects reported and stable microbial composition in the oral cavity.

- Streptococcus salivarius K12 has low pathogenic potential and is unlikely to cause disease in healthy humans. - The microbial composition of saliva did not significantly change after ingesting S. salivarius K12. - Some subjects had bacteriocin-producing S. salivarius strains in their oral cavities even after completing the course of K12 lozenges. - Counts of S. salivarius and facultatively anaerobic bacteria remained stable throughout the study.

This is from Journal of Bacteriology in 2006 at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1449041/

The results of this pilot study suggest that the administration of oropharyngeal probiotics to frontline medical staff fighting against COVID-19 significantly reduced the incidence of respiratory tract infections, shortened the duration of infections, and decreased the number of days absent from work.

- Oropharyngeal probiotic ENT-K12 prevents respiratory tract infections among frontline medical staff fighting against COVID-19. - The pilot study supports the effectiveness of the probiotic in reducing respiratory infections. - The probiotic may be beneficial for healthcare workers. - The study suggests a potential preventive measure for respiratory tract infections.

This is from Frontiers in Bioengineering and Biotechnology in 2021 at URL.

Probiotics have been suggested as potential prophylactics and therapeutics for COVID-19, but the current evidence is limited and inconclusive regarding their effectiveness in preventing or treating the disease.

- Probiotic supplements may not be universally effective and safe. - The gut microbiome may play a role in the COVID-19 pandemic. - Circadian rhythms can affect gut microbiota and overall health. - Bacterial transmission from probiotic capsules to blood has been observed in ICU patients. - There is a potential link between gut microbiota and metabolic and gastrointestinal pathology. - The interaction between drugs and the gut microbiome is an important consideration. - The gut microbiome can affect drug metabolism. - The gut microbiome is involved in maintaining barrier integrity in the colon. - Saccharomyces cerevisiae var. boulardii fungemia has been reported following probiotic treatment. - Bacteremia from probiotics has been observed in some cases.

This is from ScienceDirect in 2022 at https://www.sciencedirect.com/science/article/pii/S2405457722004521.

The article discusses the importance of the oral microbiome in periodontal health and disease, and explores potential treatment options, such as dental probiotics and oral microbiome transplantation, but further research is needed to develop innovative preventative measures and effective therapies against periodontal diseases.

- Probiotics may have health benefits for the mouth, including managing caries and periodontitis. - Oral microbiota transplantation is being studied as a potential new therapy for oral diseases. - Triphala, a herbal mouthwash, has been shown to be effective in treating gingivitis. - Photodynamic therapy using 5-aminolevulinic acid may be a promising treatment for chronic periodontitis. - Chlorhexidine gel may be effective as an adjunctive treatment for chronic periodontitis. - The oral microbiome is increasingly recognized as important for periodontal health and disease.

This is from Future Sci OA in 2023 at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445586/.

This article discusses the microbiome of the upper respiratory tract, its importance in health and disease, and the potential of probiotic therapy as a novel approach for treating allergic diseases and chronic rhinosinusitis.

- The microbiome of the upper respiratory tract plays a role in health and disease. - Probiotic therapy may be a novel approach for allergic disease. - House dust exposure may mediate gut microbiome Lactobacillus enrichment and airway immune defense against allergens and virus infection. - Regulatory dendritic cells and CD4+ Foxp3+ T cells generated by probiotics administration may suppress immune disorders. - Lactobacillus rhamnosus may prevent asthma in a mouse model. - Microbial translocation may play a role in the pathogenesis of HIV infection and AIDS. - Microbiome-based therapeutics may be effective for chronic rhinosinusitis. - Intranasal administration of Lactobacillus rhamnosus GG may prevent birch pollen-induced allergic asthma in a murine model. - Immunomodulatory supplementation with Lactobacillus rhamnosus may reduce airway inflammation in a mouse asthma model. - Probiotic E. faecalis may be an adjuvant therapy in children with recurrent rhinosinusitis. - Intragastric and intranasal administration of Lactobacillus paracasei NCC2461 may modulate allergic airway. - A topical lactic acid bacterial microbiome may be clinically effective in chronic rhinosinusitis. - Lactic acid bacterial symbionts in honeybees may be a key to honey's antimicrobial and therapeutic activities. - Continuous base identification for single-molecule nanopore DNA sequencing and real-time DNA sequencing from single polymerase molecules are promising techniques for DNA sequencing. - Pacific Biosciences sequencing of full-length 16S rRNA genes can be used for species-level bacterial community profiling of the healthy sinonasal microbiome.

This is from BMC Biol. in 2019 at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836414/.

This article discusses the microbiome of the upper respiratory tract, including its composition, how it changes with age and lifestyle, and how imbalances can lead to disease. The article also describes potential therapies, such as saline rinses and probiotics, and the challenges of studying the microbiome in the upper respiratory tract.

- The microbiome of the upper respiratory tract is still in its infancy in terms of research. - The majority of current knowledge about the URT microbiome is based on cultivation assays or next generation sequencing of segments of the bacterial 16S rRNA gene amplified from uncultured samples. - Nasal rinse is an effective, inexpensive, and simple method to treat sinonasal disorders alone or in association with other therapies to reduce medicine consumption. - Probiotic microbes can interact with other microbes of the human microbiome by production of antimicrobials, competitive colonization, and inhibition of pathogen growth. - Physicians and patients have high expectations of microbiome-driven therapies, yet most available knowledge stemming from basic research or clinical trials is far from impacting, or being implemented in, medical treatment.

This is from BMC Biology in 2019 at https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-019-0703-z.